Last reviewed · How we verify
Iomeprol 350
At a glance
| Generic name | Iomeprol 350 |
|---|---|
| Also known as | Imeron |
| Sponsor | Deutsches Herzzentrum Muenchen |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study on Sex-specific, Individualized Dose Calculation of Contrast Agent in CT Examinations (NA)
- Pericapsular Nerve Group Block: An Imaging Study for Determination of the Spread of the Injectate Using 3-D CT Scan (NA)
- Comparison of Icg's Route of Administration During Laparoscopic Cholecystectomy (NA)
- PErirenal Adipose Tissue and RenaL Hemodynamics in Patients With Heart Failure With Preserved Ejection Fraction
- A Multicenter Study of Iomeron®-400 Used With Multi-detector Computed Tomography Angiography (MDCTA) (PHASE4)
- Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography (PHASE4)
- Ultrasound Examination and Guided Injection Into the Acromio-clavicular Joint (NA)
- Iodixanol vs. Iomeprol to Prevent Contrast-Induced Nephropathy After Coronary Intervention (CONTRAST) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iomeprol 350 CI brief — competitive landscape report
- Iomeprol 350 updates RSS · CI watch RSS
- Deutsches Herzzentrum Muenchen portfolio CI